G01N 2333/91017
With definite ec number
Official title: with definite EC number (2.1.1.-)
G01N2333/91017 (With definite ec number) appears on 34 US grants and 75 published applications in this corpus.
Search patents in G01N- Granted patents
- 34
- Published applications
- 75
- Assignees
- 67
- Inventors
- 204
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 3 |
| 2011 | 0 | 1 |
| 2012 | 1 | 3 |
| 2013 | 0 | 4 |
| 2014 | 1 | 4 |
| 2015 | 5 | 6 |
| 2016 | 1 | 7 |
| 2017 | 5 | 10 |
| 2018 | 5 | 5 |
| 2019 | 3 | 6 |
| 2020 | 5 | 6 |
| 2021 | 0 | 5 |
| 2022 | 2 | 2 |
| 2023 | 3 | 1 |
| 2024 | 1 | 4 |
| 2025 | 1 | 3 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- KMT2A-MAML2 fusion molecules and uses thereof24 Feb 2026US 12,559,800 B2Foundation Medicine, Inc.
- Biomarker composition for predicting cancer malignant prognosis induced by microplastic exposure18 Feb 2025US 12,228,575 B2Korea Institute of Radiological & Medical Sciences
- Acetaminophen adducts and methods of use thereof21 May 2024US 11,987,834 B2BioVentures, LLC
- Method for treating and prognosing cancer15 Aug 2023US 11,723,948 B2Centre National de la Recherche Scientifique (CNRS)
- Clonal haematopoiesis28 Mar 2023US 11,613,786 B2President and Fellows of Harvard College
- Compositions and methods for detection of aberrant cdk5 expression8 Oct 2026US 2026/0309712 A1Arizona Board of Regents on Behalf of the University of Arizona
- Novel inhibitors of histone methyltransferase nuclear localisation20 Aug 2026US 2026/0242753 A1The Council of the Queensland Institute of Medical Research
- Method to distinguish aspartate from isoaspartate in a protein26 Feb 2026US 2026/0056205 A1Wisconsin Alumni Research Foundation
- Microenvironmental determinants of clonal hematopoiesis expansion rate14 Aug 2025US 2025/0258177 A1
- Ex vivo colonic biopsy platform to evaluate multi-omic signatures for screening candidate therapeutics31 Jul 2025US 2025/0244312 A1Athos Therapeutics, Inc.
Most cited
By later US patents
- Inhibitors of human EZH2, and methods of use thereof41US 9,175,331 B2Epizyme, Inc. · 2015
- Inhibitors of human EZH2, and methods of use thereof36US 9,334,527 B2Epizyme, Inc. · 2016
- Clonal haematopoiesis30US 10,683,552 B2Presidents and Fellows of Harvard College · 2020
- Diagnosis and treatment of cancer28US 9,040,286 B2Children's Medical Center Corporation · 2015
- Substituted indoles9US 9,932,340 B2AbbVie Inc. · 2018